依托考昔N1’-氧化物 | 325855-74-1

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 依托考昔N1’-氧化物
• 中文别名: 依托考昔N1'-氧化物；依托考昔 N-氧化物
• 英文名称: Etoricoxib-1'-N-Oxide
• 英文别名: 5-Chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-[2,3'-bipyridine] 1'-oxide；5-chloro-2-(6-methyl-1-oxidopyridin-1-ium-3-yl)-3-(4-methylsulfonylphenyl)pyridine
• CAS: 325855-74-1
• 化学式: C₁₈H₁₅ClN₂O₃S
• 分子量: 374.848
• InChiKey: KMLFAHIIJSUUPX-UHFFFAOYSA-N

物化性质

• 熔点：
  204-206°C
• 沸点：
  603.5±55.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（轻微）、DMSO（轻微、超声处理）、甲醇（轻微、加热）

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  80.9
• 氢给体数：
  0
• 氢受体数：
  4

ADMET

代谢

Etoricoxib 1'-N'-oxide是已知的依他昔布的人类代谢物。

Etoricoxib 1'-N'-oxide is a known human metabolite of etoricoxib.

来源:NORMAN Suspect List Exchange

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  -20°C，干燥密封

反应信息

• 作为反应物：
  描述：

  依托考昔N1’-氧化物 在 乙酸酐 、 sodium hydroxide 、 potassium carbonate 作用下， 以 乙醇 、 甲醇 为溶剂， 反应 1.5h， 以67%的产率得到6'-去甲基-6'-甲基羟基依托昔
  参考文献：
  名称：

  In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663)

  摘要：

  Characterization of the metabolites of the COX-2 inhibitor etorieoxib (MK-0663 and L-791,456) produced in vitro indicate formation of an N-oxide pyridine: and hydroxymethyl pyridine that van further be glucuronidated or oxidized to an acid. Significant turnover is observed in human hepatocytes. Several CYPs are involved in the oxidative biotranformatiuns and. From in vitro studies, etoricoxib is not a potent CYP3A4 inducer or inhibitor. Based on an in vitro whole blood assay, none of the metabolites of etoricoxib inhibits COX-I or contributes significantly to the inhibition of COX-2. (C) 2001 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(01)00135-4
• 作为产物：
  描述：

  依托考昔 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以62%的产率得到依托考昔N1’-氧化物
  参考文献：
  名称：

  In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663)

  摘要：

  Characterization of the metabolites of the COX-2 inhibitor etorieoxib (MK-0663 and L-791,456) produced in vitro indicate formation of an N-oxide pyridine: and hydroxymethyl pyridine that van further be glucuronidated or oxidized to an acid. Significant turnover is observed in human hepatocytes. Several CYPs are involved in the oxidative biotranformatiuns and. From in vitro studies, etoricoxib is not a potent CYP3A4 inducer or inhibitor. Based on an in vitro whole blood assay, none of the metabolites of etoricoxib inhibits COX-I or contributes significantly to the inhibition of COX-2. (C) 2001 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(01)00135-4

文献信息

• A General [3 + 2 + 1] Annulation Strategy for the Preparation of Pyridine <i>N</i>-Oxides
  作者：Ian W. Davies、Jean-François Marcoux、Paul J. Reider

  DOI：10.1021/ol006831r

  日期：2001.1.1

  [figure: see text] Stabilized ketone, aldehyde, and ester enolates react with vinamidinium hexafluorophosphate salts and hydroxylamine hydrochloride to give access to the corresponding pyridine N-oxides. The annulation reactions proceed in good to excellent yields with vinamidinium salts with a range of beta-substituents (R3 = halo, aryl, nitro, trifluoromethyl).

  稳定的酮，醛和酯烯酸酯与六氟磷酸乙烯胺盐和羟胺盐酸盐反应，可得到相应的吡啶N-氧化物。用具有一系列β-取代基（R3 =卤素，芳基，硝基，三氟甲基）的钒胺盐，环化反应以良好的产率进行，收率很好。
• In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663)
  作者：Nathalie Chauret、James A Yergey、Christine Brideau、Richard W Friesen、Joseph Mancini、Denis Riendeau、José Silva、Angela Styhler、Laird A Trimble、Deborah A Nicoll-Griffith

  DOI：10.1016/s0960-894x(01)00135-4

  日期：2001.4

  Characterization of the metabolites of the COX-2 inhibitor etorieoxib (MK-0663 and L-791,456) produced in vitro indicate formation of an N-oxide pyridine: and hydroxymethyl pyridine that van further be glucuronidated or oxidized to an acid. Significant turnover is observed in human hepatocytes. Several CYPs are involved in the oxidative biotranformatiuns and. From in vitro studies, etoricoxib is not a potent CYP3A4 inducer or inhibitor. Based on an in vitro whole blood assay, none of the metabolites of etoricoxib inhibits COX-I or contributes significantly to the inhibition of COX-2. (C) 2001 Published by Elsevier Science Ltd.